New cancer drug JMT108 enters human testing
NCT ID NCT06877650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an experimental drug called JMT108, given alone or with other cancer drugs (pembrolizumab or ivonescimab), in people with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. About 436 adults are being enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JMT108 (an experimental drug given by IV every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1/2 trial, so the main goal is safety and dosing, not yet proof of effectiveness. Many experimental cancer drugs fail to show benefit in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••